We are live on ! Find out more
OPNT

Opiant Pharmaceuticals, Inc. Common Stock
OPNT

Delisted

OPNT was delisted on the 1st of March, 2023.

Back to rankings

37 hedge funds and large institutions have $41.2M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more capital invested

Capital invested by funds: $19.4M → $41.2M (+$21.8M)

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

16% more funds holding

Funds holding: 32 → 37 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

Holders
37
Holders Change
+5
Holders Change %
+15.63%
% of All Funds
0.59%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
7
Reduced
11
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WSL
Western Standard LLC
California
+$6.5M
2
Morgan Stanley
Morgan Stanley
New York
+$2.92M
3
NYLIM
New York Life Investment Management
New York
+$949K
4
CL
CSS LLC
Illinois
+$940K
5
RA
Ramius Advisors
New York
+$848K

Top Sellers

Rank Fund Capital Flow
1
HP
HealthInvest Partners
Sweden
-$2.26M
2
SCM
Stonepine Capital Management
Oregon
-$1.64M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.36M
4
Wells Fargo
Wells Fargo
California
-$1.05M
5
EIM
Essex Investment Management
Massachusetts
-$507K
Name Holding Trade Value Shares
Change 		Change in
Stake
WSL
1
Western Standard LLC
California
$8.6M +$6.5M +424,080 New
ACA
2
Apis Capital Advisors
New York
$4.34M +$153K +10,000 +5%
Morgan Stanley
3
Morgan Stanley
New York
$4.01M +$2.92M +190,441 +2,641%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.87M +$55.4K +3,615 +2%
Renaissance Technologies
5
Renaissance Technologies
New York
$2.97M -$468K -30,500 -17%
Wells Fargo
6
Wells Fargo
California
$2.77M -$1.05M -68,303 -33%
NYLIM
7
New York Life Investment Management
New York
$1.26M +$949K +61,912 New
CL
8
CSS LLC
Illinois
$1.24M +$940K +61,349 New
PHP
9
Parkman Healthcare Partners
Connecticut
$1.22M -$254K -16,587 -22%
RA
10
Ramius Advisors
New York
$1.12M +$848K +55,298 New
YCM
11
Yakira Capital Management
Connecticut
$1.1M +$833K +54,371 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$985K -$2.08K -136 -0.3%
BMCM
13
Black Maple Capital Management
Wisconsin
$985K +$744K +48,548 New
E
14
Ergoteles
New York
$876K +$662K +43,200 New
SSA
15
Schonfeld Strategic Advisors
New York
$858K +$648K +42,300 New
BlackRock
16
BlackRock
New York
$800K -$7.62K -497 -1%
Northern Trust
17
Northern Trust
Illinois
$784K -$3.76K -245 -0.6%
GF
18
Gabelli Funds
New York
$753K +$569K +37,119 New
GCIA
19
Gabelli & Co Investment Advisers
New York
$420K +$317K +20,700 New
Two Sigma Advisers
20
Two Sigma Advisers
New York
$377K -$73.6K -4,800 -21%
State Street
21
State Street
Massachusetts
$326K +$42.9K +2,800 +21%
FLC
22
Fifth Lane Capital
Texas
$304K +$230K +15,000 New
Citadel Advisors
23
Citadel Advisors
Florida
$287K +$217K +14,169 New
HM
24
Harvest Management
New York
$243K +$184K +12,000 New
Mariner
25
Mariner
Kansas
$214K -$46K -3,000 -22%
1
2

OPNT Hedge Fund Activity: Q4 2022 in Review

37 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2022, worth a combined $41.2M — up 112% from $19.4M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OPNT positions and 11 closed out — a net gain of 6 holders — while 7 added to existing stakes and 11 trimmed.

The largest buyer was Western Standard LLC, opening a new position worth an estimated $6.5M. The largest seller was HealthInvest Partners, exiting entirely with an estimated $2.26M sold.

  • 37 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2022, up from 32 in Q3 2022.
  • Funds reported $41.2M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2022, up 112% quarter-over-quarter.
  • 17 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 11 closed out, a net change of +6 holders.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Western Standard LLC, an estimated $6.5M added.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was HealthInvest Partners, an estimated $2.26M sold.

Based on aggregated 13F filings for Q4 2022.